PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

Phase 2positiverezatapoptPositive

AI Analysis

Summary

PMV Pharmaceuticals announced updated interim ovarian cancer data from the PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy in patients with TP53 Y220C advanced solid tumors. The data readout represents positive clinical progress for the precision oncology program.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Updated interim ovarian cancer data from PYNNACLE Phase 2 pivotal trial announced

Importance:7/10

Sentiment:

0.65

precision oncologyp53 targetingovarian cancermonotherapyregistrational trialPYNNACLE

Related Companies

$PMVP

Read the original article

Published by GlobeNewswire Clinical Studies on August 31, 2026 8:01 PM

Read Original